We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Acharya failed to qualify or properly monitor its raw material storage area, posing a risk for the starting material metronidazole, Swissmedic said. Read More
The FDA served Alkermes with a warning letter for serious violations in the promotion of its opioid addiction treatment Vivitrol (naltrexone for extended-release injectable suspension). Read More